Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity
Menée in vitro et à l'aide de modèles murins, cette étude met en évidence l'intérêt d'anticorps monoclonaux ciblant le récepteur 2 du TNF pour activer les lymphocytes T CD8+ et favoriser la réponse antitumorale du système immunitaire
Tumor necrosis factor receptor 2 (TNFR2) is the alternate receptor for TNF and can mediate both pro- and anti-inflammatory activities of T cells. Although TNFR2 has been linked to enhanced suppressive activity of regulatory T cells (Tregs) in autoimmune diseases, the viability of TNFR2 as a target for cancer immunotherapy has been underappreciated. Here, we show that new murine monoclonal anti-TNFR2 antibodies yield robust antitumor activity and durable protective memory in multiple mouse cancer cell line models. The antibodies mediate potent Fc-dependent T cell costimulation and do not result in significant depletion of Tregs. Corresponding human agonistic monoclonal anti-TNFR2 antibodies were identified and also had antitumor effects in humanized mouse models. Anti-TNFR2 antibodies could be developed as a novel treatment option for patients with cancer.